Get the Stockscreener App
11.47
8.11%
0.86
After Hours:
11.47
Atara Biotherapeutics Inc stock is traded at $11.47, with a volume of 65,670.
It is up +8.11% in the last 24 hours and up +26.74% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$10.61
Open:
$10.64
24h Volume:
65,670
Relative Volume:
0.46
Market Cap:
$66.06M
Revenue:
$62.39M
Net Income/Loss:
$-181.05M
P/E Ratio:
-3.9014
EPS:
-2.94
Net Cash Flow:
$-142.49M
1W Performance:
-4.42%
1M Performance:
+26.74%
6M Performance:
-34.44%
1Y Performance:
-19.79%
1-Day Range:
$10.38
$11.48
1-Week Range:
$10.03
$12.22
52-Week Range:
$6.50
$39.50
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4244
Address
2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ATRA | 11.47 | 66.06M | 62.39M | -181.05M | -142.49M | -2.94 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Atara Biotherapeutics CEO sells shares worth $18,633 By Investing.com - Investing.com South Africa
Atara biotherapeutics CFO Eric Hyllengren sells $15,274 in stock By Investing.com - Investing.com Nigeria
Atara biotherapeutics EVP sells $11,198 in stock By Investing.com - Investing.com Australia
Atara biotherapeutics CFO Eric Hyllengren sells $15,274 in stock - Investing.com India
Atara biotherapeutics EVP sells $11,198 in stock - Investing.com India
Atara Biotherapeutics CEO sells shares worth $18,633 - Investing.com
FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility - GlobeNewswire Inc.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics Inc - GuruFocus.com
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics Reports Q3 2024 Financial Progress - TipRanks
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference - Business Wire
Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel raises Atara Bio shares target, keeps hold rating ahead of clinical data - Investing.com UK
Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00 - MarketBeat
Atara Biotherapeutics: Q3 Earnings Snapshot - Houston Chronicle
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M - Marketscreener.com
Atara Bio Q3 Revenue Soars 1,814% to $40.2M, FDA Decision Looms for Tab-cel Drug | ATRA Stock News - StockTitan
(ATRA) On The My Stocks Page - Stock Traders Daily
Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Business Wire
Vanguard Group Inc's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus.com
Net Present Value Model: Atara Biotherapeutics Inc’s ATA-3219 - GlobalData
Hemophagocytic Lymphohistiocytosis Market to Reach New Heights in Growth by 2034, DelveInsight Predict | Incyte, Novartis, Atara Biotherapeutics, Bellicum Pharma - The Globe and Mail
(ATRA) Trading Signals - Stock Traders Daily
Atara Biotherapeutics names new COO By Investing.com - Investing.com Australia
Atara Biotherapeutics names new COO - Investing.com
Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer - Marketscreener.com
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How to Take Advantage of moves in (ATRA) - Stock Traders Daily
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - Yahoo Finance
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily
How To Trade (ATRA) - Stock Traders Daily
Atara Therapeutics appoints Cokey Nguyen as chief executive - The Pharma Letter
Atara Biotherapeutics Sees Its Stock Price Rise - Los Angeles Business Journal
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On? - MSN
Atara Biotherapeutics Inc [ATRA] President and CEO makes an insider purchase of 3,038 shares worth 20139.0. - Knox Daily
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal
Atara Biotherapeutics secures $36 million in stock sale - Investing.com
Atara Biotherapeutics Shares Climb on $36 Million Direct Offering - MarketWatch
Atara Biotherapeutics Announces Board Appointment and Capital Raise - TipRanks
Atara Biotherapeutics Announces $36 Million Registered Direct Offering - StockTitan
Atara Biotherapeutics Inc’s latest rating changes from various analysts - Knox Daily
(ATRA) Proactive Strategies - Stock Traders Daily
Atara Biotherapeutics EVP sells over $7k in company stock - Investing.com India
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hyllengren Eric J | EVP, CFO and COO |
Nov 18 '24 |
Sale |
11.20 |
1,364 |
15,274 |
23,392 |
| Nguyen AnhCo | President and CEO |
Nov 18 '24 |
Sale |
11.20 |
1,664 |
18,633 |
77,454 |
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):